Skip to Content

Join the 'Calcipotriene' group to help and get support from people like you.

Calcipotriene News

Retail Prices of Dermatology Drugs Skyrocket

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – Patients using prescription creams, gels, sprays and pills for skin conditions may shell out substantially more at the pharmacy than they did just six years ago, a new study suggests. Between 2009 and 2015, retail prices of brand-name dermatologic drugs rose 401 percent, on average, study authors reported Nov. 25 in JAMA Dermatology. Even generics have succumbed to price inflation, up 279 percent between 2011 and 2014, based on the drugs surveyed. Price increases for skin treatments far outpaced the general inflation rate of 11 percent during the six-year study period, the researchers said. "Cancer drugs were the worst in terms of the numbers" – up 1,240 percent or nearly $11,000 over the six-year study period – primarily because of two medicines, said Dr. Steven Rosenberg, voluntary professor of dermatology at the University of Miami Miller School of ... Read more

Related support groups: Monistat, RID, Monistat 3, Eczema, Voltaren Gel, Monistat 7, Dermatitis, Clobetasol, Contact Dermatitis, Bactroban, Mupirocin, Therapeutic, Maintain, Hypercare, Drysol, Sulfur, Fluocinonide, Retin-A, Efudex, Epiduo

Worse Psoriasis, Less Healthy Arteries, Study Finds

Posted 8 Oct 2015 by Drugs.com

THURSDAY, Oct. 8, 2015 – The skin disorder psoriasis appears linked with artery inflammation, raising the odds for heart disease, a new study says. "As the amount of psoriasis increases, the amount of blood vessel inflammation increases," said senior investigator Dr. Nehal Mehta, a clinical investigator with the U.S. National Heart, Lung, and Blood Institute. His team also found that even mild psoriasis may indicate an increased risk for heart attack and stroke. Just one psoriasis skin patch, or plaque, "might be biologically active, causing low-grade inflammation and starting a cascade, speeding up their blood vessel disease," Mehta said. "People really should know that psoriasis is not just a cosmetic disease," he added. However, these study findings only show an association between psoriasis and blood vessel inflammation, not a direct cause-and-effect relationship, Mehta said. His ... Read more

Related support groups: Methotrexate, Psoriasis, Inflammatory Conditions, Plaque Psoriasis, Coronary Artery Disease (CAD), Soriatane, Dovonex, Tazorac, Acute Coronary Syndrome, Oxsoralen, Taclonex, Acitretin, Calcipotriene, Tazarotene, Resorcinol, Acute Coronary Syndrome - Prophylaxis, Anthralin, Vectical, Dritho-Scalp, Psoriatec

Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%

Posted 18 Oct 2010 by Drugs.com

Research Triangle Park, N.C. – October 12, 2010 – Stiefel, a GSK company, today announced that the U.S. Food and Drug Administration (FDA) has approved Sorilux (calcipotriene) Foam, 0.005%, for the topical treatment of plaque psoriasis in patients aged 18 years and older. Stiefel received the approval approximately two weeks in advance of the anticipated FDA action date. Plaque psoriasis is a chronic, non-contagious, inflammatory skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp and knees but can also affect other parts of the body. "Plaque psoriasis affects up to six million Americans each year," said Bill Humphries, president, Stiefel, "Which is why Stiefel is so committed to bringing new therapy options, like Sorilux Foam, to patients." Sorilux Foam was found to be effective in treating mild to moderate plaque psoriasis. It con ... Read more

Related support groups: Psoriasis, Calcipotriene

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriasis

Related Drug Support Groups

Dovonex, Donovex, Sorilux, Calcitrene

Calcipotriene Patient Information at Drugs.com